Subcutaneous administration of isatuximab in patients with multiple myeloma by an on-body delivery system: results of a nurse survey
{{output}}
Introduction: Subcutaneous (SC) administration of the anti-CD38 antibody isatuximab (Isa) by an on-body delivery system (OBDS), plus pomalidomide-dexamethasone, has demonstrated safety and efficacy comparable to intravenous (IV) ... ...
